- Olon plans to acquire HuvePharma Italia Srl, including its Garessio site.
- The acquisition aims to increase Olon’s API production capacity and integrate the assets into its global network.
Olon, a chemical-pharmaceutical group, has announced its intention to acquire HuvePharma Italia Srl and its manufacturing site in Garessio, Cuneo, Italy. The acquisition involves integrating HuvePharma Italia’s operations, including its production site, workforce, and product portfolio, into Olon’s existing network. Olon currently operates nine manufacturing plants in Italy, bringing its total reaction capacity to 3,250 cubic meters.
HuvePharma Italia Srl is known for its development and production of active pharmaceutical ingredients (APIs) and advanced intermediates. The Garessio plant will be revitalised to achieve full production capacity as part of Olon’s expansion strategy.
Paolo Tubertini, CEO of Olon Group, stated, “The acquisition supports the implementation of the Group’s medium to long term strategy and the achievement of our business objectives.” He added that integrating HuvePharma Italia will enhance Olon’s API production capacity and leverage its existing manufacturing network.
Stay ahead of trends and best practices
